BroadSoft Hub Now Commercially Available For AI-Powered Workforce Communications
Mar 27, 2017 11:02 am UTC| Business
GAITHERSBURG, Md., March 27, 2017 -- BroadSoft, Inc. (NASDAQ:BSFT), a global unified communication software as a service (UCaaS) leader, today announced the commercial availability of Hub, a BroadSoft Business cloud...
ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
Mar 27, 2017 11:02 am UTC| Business
LEIDEN, the Netherlands, March 27, 2017 -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr. Rodman has had a long career in drug...
Mar 27, 2017 11:02 am UTC| Business
PHOENIX, March 27, 2017 -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that, effective April 17, 2017, Saeed Motahari, will become the Company’s President and Chief Executive...
Bazaarvoice and TurnTo Form Partnership to Bring More Consumer-Generated Content to Retailers
Mar 27, 2017 11:02 am UTC| Business
AUSTIN, Texas and NEW YORK, March 27, 2017 -- Bazaarvoice, Inc. (Nasdaq:BV) and TurnTo Networks announced today they have reached an agreement to offer TurnTo’s brand clients the opportunity to syndicate their ratings...
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2016 Financial Results
Mar 27, 2017 11:02 am UTC| Business
NEWTOWN, Pa., March 27, 2017 -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a...
ZIOPHARM Appoints Amy Trevvett Vice President of Investor Relations and Corporate Communications
Mar 27, 2017 11:02 am UTC| Business
BOSTON, March 27, 2017 -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced the appointment of Amy Trevvett as Vice President of Investor Relations and...
Mar 27, 2017 11:02 am UTC| Business
SANTA MONICA, Calif., March 27, 2017 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced...